A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

This study is not yet open for participant recruitment.

Verified by Genentech, May 2007

Sponsored by:	Genentech
Information provided by:	Genentech
ClinicalTrials.gov Identifier:	NCT00477425

Purpose

This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.

Condition	Phase
Carcinoma	Phase IV

Drug Information available for: Bevacizumab

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Prospective Study
Official Title:	Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

Further study details as provided by Genentech:

Estimated Enrollment:	150
Study Start Date:	June 2007

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Signed Informed Consent Form
Enrollment in one of a list of certain randomized, controlled bevacizumab trials

Exclusion Criteria:

Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
Congenital long QT syndrome
Family history of long QT syndrome
Clinically significant bradycardia (defined as < 50 beats/minute)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00477425

Sponsors and Collaborators

Genentech

Investigators

Study Director:

Jane Huang, M.D.

Genentech

More Information

Study ID Numbers:	AVF4223g
Study First Received:	May 21, 2007
Last Updated:	May 21, 2007
ClinicalTrials.gov Identifier:	NCT00477425
Health Authority:	United States: Food and Drug Administration

Keywords provided by Genentech:

Avastin

Study placed in the following topic categories:

Bevacizumab
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Histologic Type
Antineoplastic Agents
Therapeutic Uses
Growth Substances

Physiological Effects of Drugs
Growth Inhibitors
Angiogenesis Modulating Agents
Angiogenesis Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009